PRLD

Business Context and Reporting Period

Prelude Therapeutics Inc. (PRLD) is a precision oncology company focused on developing novel cancer medicines for underserved patients. The company operates as a single segment and is classified as a "smaller reporting company." This Form 10-K covers the fiscal year ended December 31, 2025. As of December 31, 2025, the company had 79 full-time employees and maintains its principal executive offices in Wilmington, Delaware.

Key Financial Metrics

Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue and incurs operating losses.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased by $5.1 million (73%) to $12.1 million in 2025. This was driven by $2.6 million recognized from an Exclusive Option Agreement with Incyte Corporation and $9.5 million from amended and expanded collaboration agreements with AbCellera Biologics.
• Reduced Net Loss: Net loss decreased by $27.7 million (22%) to $99.5 million, primarily due to lower operating expenses.
• Expense Reductions:
  • R&D Expenses: Decreased by $23.7 million to $94.3 million. This reduction was attributed to lower stock-based compensation ($6.9 million in 2025 vs. $12.1 million in 2024) and decreased costs associated with discontinued clinical trials (specifically PRT3789 and PRT2527).
  • G&A Expenses: Decreased by $6.3 million to $22.4 million, driven by reduced stock-based compensation and employee-related expenses following a workforce reduction.
• Strategic Transactions:
  • Incyte Agreement: In November 2025, the company entered an Exclusive Option Agreement with Incyte for its JAK2V617F inhibitor program. Prelude received $35 million in cash and a $25 million equity investment. Incyte has the option to acquire the program for $100 million, with potential total payments reaching $910 million including milestones.
  • AbCellera Expansion: The company amended and expanded its collaboration with AbCellera, receiving $12.5 million in upfront payments ($6.5 million and $6.0 million) for non-exclusive licenses to degrader payloads.
• Program Pause: In November 2025, the company announced the pause of clinical development for its SMARCA2 degrader program (PRT3789 and PRT7732) to prioritize resources for JAK2V617F and KAT6A programs.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($106.4 million as of year-end) to fund operating expenses and capital expenditures into the second quarter of 2027.
• Development Milestones:
  • JAK2V617F (PRT12396): Received FDA IND clearance in February 2026; Phase 1 study initiation anticipated in Q2 2026.
  • KAT6A Selective Degrader: IND filing expected in mid-2026; Phase 1 study initiation anticipated in H2 2026.
• Key Risks:
  • Capital Requirements: The company has never generated product revenue and expects to incur continued losses. It will require substantial additional funding to pursue its business objectives.
  • Development Uncertainty: Success depends on the successful completion of clinical trials and regulatory approval, which are uncertain and costly.
  • Stock Price Volatility: The stock price ranged from $0.61 to $3.98 in 2025. The company previously received a notice of non-compliance with Nasdaq's minimum bid price requirement in March 2025 but regained compliance in September 2025.
  • Third-Party Reliance: The company relies on third parties for manufacturing and clinical trials, creating supply chain and execution risks.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projection that current liquidity ($106.4 million) will sustain operations through Q2 2027, considering the burn rate and potential delays in clinical trials.
• Incyte Option Exercise: Monitor the status of the Incyte Exclusive Option Agreement. The $100 million acquisition option and subsequent milestones are contingent on the program advancing to pre-defined milestones within the option period.
• Revenue Recognition: Review the accounting treatment of the Incyte and AbCellera agreements under ASC 606, specifically the timing of revenue recognition for the upfront payments versus the performance obligations.
• Clinical Trial Progress: Track the initiation dates for the Phase 1 studies of PRT12396 (JAK2V617F) and the KAT6A degrader, as delays could impact the Incyte option timeline and future funding needs.
• Workforce Reduction Impact: Assess the long-term impact of the 27% workforce reduction on the company's ability to execute its remaining clinical programs efficiently.